These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19866482)

  • 1. Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination.
    Castellanos M; Cinza Z; Dorta Z; Veliz G; Vega H; Lorenzo I; Ojeda S; Dueñas-Carrera S; Alvarez-Lajonchere L; Martínez G; Ferrer E; Limonta M; Linares M; Ruiz O; Acevedo B; Torres D; Márquez G; Herrera L; Arús E
    J Gene Med; 2010 Jan; 12(1):107-16. PubMed ID: 19866482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial.
    Alvarez-Lajonchere L; Shoukry NH; Grá B; Amador-Cañizares Y; Helle F; Bédard N; Guerra I; Drouin C; Dubuisson J; González-Horta EE; Martínez G; Marante J; Cinza Z; Castellanos M; Dueñas-Carrera S
    J Viral Hepat; 2009 Mar; 16(3):156-67. PubMed ID: 19017255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C.
    Kallinowski B; Jilg W; Buchholz L; Stremmel W; Engler S
    Z Gastroenterol; 2003 Oct; 41(10):983-90. PubMed ID: 14562195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins.
    Satoi J; Murata K; Lechmann M; Manickan E; Zhang Z; Wedemeyer H; Rehermann B; Liang TJ
    J Virol; 2001 Dec; 75(24):12121-7. PubMed ID: 11711603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma.
    Böcher WO; Herzog-Hauff S; Schlaak J; Meyer zum Büschenfeld KH; Löhr HF
    Hepatology; 1999 Jan; 29(1):238-44. PubMed ID: 9862872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
    Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
    Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.
    Klade CS; Wedemeyer H; Berg T; Hinrichsen H; Cholewinska G; Zeuzem S; Blum H; Buschle M; Jelovcan S; Buerger V; Tauber E; Frisch J; Manns MP
    Gastroenterology; 2008 May; 134(5):1385-95. PubMed ID: 18471515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4(+) Th1 cell responses in vivo.
    Gao M; Wang HP; Wang YN; Zhou Y; Wang QL
    Vaccine; 2006 Jun; 24(26):5491-7. PubMed ID: 16725235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of the "isolated anti-HBc" serological pattern determinated by the serological response to the vaccination against Hepatitis B].
    Coz Yataco A; Lozano Miranda A; Samalvides Cuba F; Antunez de Mayolo Ramis E
    Rev Gastroenterol Peru; 2005; 25(3):254-8. PubMed ID: 16237469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C.
    Wiedmann M; Liebert UG; Oesen U; Porst H; Wiese M; Schroeder S; Halm U; Mössner J; Berr F
    Hepatology; 2000 Jan; 31(1):230-4. PubMed ID: 10613751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
    Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
    Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.
    Vidalin O; Fournillier A; Renard N; Chen M; Depla E; Boucreux D; Brinster C; Baumert T; Nakano I; Fukuda Y; Liljeström P; Trépo C; Inchauspé G
    Virology; 2000 Oct; 276(2):259-70. PubMed ID: 11040118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.
    Bialek SR; Bower WA; Novak R; Helgenberger L; Auerbach SB; Williams IT; Bell BP
    Pediatr Infect Dis J; 2008 Oct; 27(10):881-5. PubMed ID: 18756185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of oral immune regulation towards liver-extracted proteins for treatment of chronic HBV and HCV hepatitis: results of a phase I clinical trial.
    Israeli E; Safadi R; Melhem A; Pappo O; Shibolet O; Klein A; Hemed N; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Liver Int; 2004 Aug; 24(4):295-307. PubMed ID: 15287852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B vaccination in patients with chronic hepatitis C.
    Lee SD; Chan CY; Yu MI; Lu RH; Chang FY; Lo KJ
    J Med Virol; 1999 Dec; 59(4):463-8. PubMed ID: 10534727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases.
    Wörns MA; Teufel A; Kanzler S; Shrestha A; Victor A; Otto G; Lohse AW; Galle PR; Höhler T
    Am J Gastroenterol; 2008 Jan; 103(1):138-46. PubMed ID: 17970833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.
    Mancini-Bourgine M; Fontaine H; Bréchot C; Pol S; Michel ML
    Vaccine; 2006 May; 24(21):4482-9. PubMed ID: 16310901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine.
    Shafran SD; Mashinter LD; Lindemulder A; Taylor GD; Chiu I
    HIV Med; 2007 Jul; 8(5):295-9. PubMed ID: 17561875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.
    Li X; Yang X; Li L; Liu H; Liu J
    Vaccine; 2006 Apr; 24(16):3321-31. PubMed ID: 16472546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.